Company intelligence / Profile preview

Ocera Therapeutics

Palo Alto, California, United Statesmallinckrodt.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

OCR-002 was being studied in a Phase 2b trial (STOP-HE) for treatment of hepatic encephalopathy. The company was developing both intravenous and oral formulations of OCR-002. Phase 1 trials of the oral formulation showed it to be safe and well-tolerated.

Therapeutic areas: GastroenterologyMetabolic Disorders
Modalities: Small molecules (ammonia scavenger)
Industry: Biotech

Drug pipeline

1 asset

OCR-002

Phase 2

Indications: Hepatic encephalopathy

Beyond the preview

Go deeper on Ocera Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocera Therapeutics.

Explore the full profile